Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation

Signal Transduct Target Ther. 2021 Aug 26;6(1):318. doi: 10.1038/s41392-021-00737-7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Administration, Intranasal
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Drug Repositioning
  • Humans
  • SARS-CoV-2

Substances

  • Antiviral Agents